| Literature DB >> 11224527 |
Y Latchman1, C R Wood, T Chernova, D Chaudhary, M Borde, I Chernova, Y Iwai, A J Long, J A Brown, R Nunes, E A Greenfield, K Bourque, V A Boussiotis, L L Carter, B M Carreno, N Malenkovich, H Nishimura, T Okazaki, T Honjo, A H Sharpe, G J Freeman.
Abstract
Programmed death I (PD-I)-deficient mice develop a variety of autoimmune-like diseases, which suggests that this immunoinhibitory receptor plays an important role in tolerance. We identify here PD-1 ligand 2 (PD-L2) as a second ligand for PD-1 and compare the function and expression of PD-L1 and PD-L2. Engagement of PD-1 by PD-L2 dramatically inhibits T cell receptor (TCR)-mediated proliferation and cytokine production by CD4+ T cells. At low antigen concentrations, PD-L2-PD-1 interactions inhibit strong B7-CD28 signals. In contrast, at high antigen concentrations, PD-L2-PD-1 interactions reduce cytokine production but do not inhibit T cell proliferation. PD-L-PD-1 interactions lead to cell cycle arrest in G0/G1 but do not increase cell death. In addition, ligation of PD-1 + TCR leads to rapid phosphorylation of SHP-2, as compared to TCR ligation alone. PD-L expression was up-regulated on antigen-presenting cells by interferon gamma treatment and was also present on some normal tissues and tumor cell lines. Taken together, these studies show overlapping functions of PD-L1 and PD-L2 and indicate a key role for the PD-L-PD-1 pathway in regulatingT cell responses.Entities:
Mesh:
Substances:
Year: 2001 PMID: 11224527 DOI: 10.1038/85330
Source DB: PubMed Journal: Nat Immunol ISSN: 1529-2908 Impact factor: 25.606